Vaginal and rectal topical microbicide development: Safety and efficacy of 1.0% savvy (C31G) in the pigtailed macaque

被引:24
|
作者
Patton, Dorothy L.
Sweeney, Yvonne T. Cosgrove
Balkus, Jennifer E.
Hillier, Sharon L.
机构
[1] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
[2] Univ Pittsburgh, Magee Womens Hosp, Pittsburgh, PA 15213 USA
关键词
D O I
10.1097/01.olq.0000216022.18321.d3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: A 1.0% gel formulation of C31G, a surfactant, has been shown to have in vitro antiviral and antibacterial activity. Goal: The goal of this study was to evaluate the safety and efficacy of vaginal and rectal applications of 1.0% Savvy (C31G) in the non-human primate model. Study Design: The safety of repeated 1.0% C31G application was evaluated by microflora, pH, vaginal biopsy, colposcopy, and rectal lavage. Efficacy in preventing chlamydial infection was documented by culture, nucleic acid amplification tests, and serology. Results: Repeated applications of Savvy (1.0% C31G) were not associated with significant changes in pH, microflora, or inflammatory infiltrates on tissues. No significant differences in epithelia] desquamation were noted after rectal product use compared with placebo. Four of 6 animals were protected from chlamydial infection after pretreatment with Savvy. C31G was shown to be safe to both vaginal and rectal mucosal tissues and to the microflora with repeated daily use. Conclusion: Savvy has an acceptable safety profile after repeated vaginal and rectal use. A single intravaginal application of 1.0% C31G provided partial protection from acquiring cervical chlamydial infection.
引用
收藏
页码:691 / 695
页数:5
相关论文
共 8 条
  • [1] A Summary of Preclinical Topical Microbicide Rectal Safety and Efficacy Evaluations in a Pigtailed Macaque Model
    Patton, Dorothy L.
    Sweeney, Yvonne T. Cosgrove
    Paul, Kathleen J.
    SEXUALLY TRANSMITTED DISEASES, 2009, 36 (06) : 350 - 356
  • [2] Comparative safety evaluation of the candidate vaginal microbicide, C31G
    Catalone, BJ
    Kish-Catalone, TM
    Neely, EB
    Budgeon, LR
    Ferguson, ML
    Stiller, C
    Miller, SR
    Malamud, D
    Krebs, FC
    Howett, MK
    Wigdahl, B
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) : 1509 - 1520
  • [3] A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model
    Patton, Dorothy L.
    Sweeney, Yvonne T. Cosgrove
    Paul, Kathleen J.
    SEXUALLY TRANSMITTED DISEASES, 2008, 35 (10) : 889 - 897
  • [4] The distribution of a 3.5 ml (1.0%) C31G vaginal gel (Savvy) using Magnetic Resonence Imaging.
    Timbers, K
    Barnhart, KT
    Pretorius, ES
    Marunich, R
    Hummel, A
    Malamud, D
    FERTILITY AND STERILITY, 2003, 80 : S219 - S219
  • [5] SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in Nigeria
    Feldblum, Paul J.
    Adeiga, Adesina
    Bakare, Rashidi
    Wevill, Silver
    Lendvay, Anja
    Obadaki, Fatimah
    Olayemi, M. Onikepe
    Wang, Lily
    Nanda, Kavita
    Rountree, Wes
    PLOS ONE, 2008, 3 (01):
  • [6] Distribution of a 3.5-mL (1.0%) C31G vaginal gel using magnetic resonance imaging
    Barnhart, KT
    Pretorius, ES
    Timbers, K
    Shera, D
    Shabbout, M
    Malamud, D
    CONTRACEPTION, 2005, 71 (05) : 357 - 361
  • [7] Contraceptive Efficacy, Acceptability, and Safety of C31G and Nonoxynol-9 Spermicidal Gels A Randomized Controlled Trial
    Burke, Anne E.
    Barnhart, Kurt
    Jensen, Jeffrey T.
    Creinin, Mitchell D.
    Walsh, Terri L.
    Wan, Livia S.
    Westhoff, Carolyn
    Thomas, Michael
    Archer, David
    Wu, Hongsheng
    Liu, James
    Schlaff, William
    Carr, Bruce R.
    Blithe, Diana
    OBSTETRICS AND GYNECOLOGY, 2010, 116 (06): : 1265 - 1273
  • [8] A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II
    Mauck, CK
    Weiner, DH
    Creinin, MD
    Barnhart, KT
    Callahan, MM
    Bax, R
    CONTRACEPTION, 2004, 70 (03) : 233 - 240